Franklin Templeton Unveils New US Mega Cap ETF in Europe
Franklin Templeton has expanded its U.S. equity suite in Europe with the launch of a U.S. megacap ETF.
The Franklin US Mega Cap 100 UCITS ETF (USMC) will be listed on the London Stock Exchange (LSE), Deutsche Borse, Euronext Paris and Borsa Italiana with a total expense ratio (TER) of 0.09%.
USMC tracks the Solactive US Mega Cap 100 Select index, which offers exposure to 100 largest companies in the Solactive GBS United States 500 index.
The index's top holdings include: Nvidia Corp. (NVDA), Apple Inc. (AAPL), Amazon.com Inc. (AMZN), Microsoft Corp. (MSFT) and AT&T Inc. (T).
Caroline Baron (pictured), head of ETF distribution for EMEA at Franklin Templeton, said, 'Looking back 30 years, the largest 100 securities in U.S. equities have captured greater market upside than a broader index such as the S&P 500.
'This ETF can be utilised by investors as a nimble tool to dial up U.S. equity market exposure or quickly implement a risk-on trade, offering a distinct risk-return profile.'
ETFs that offer a slice of the "top" constituents in a given index are on the rise in Europe. BlackRock Inc. (BLK) launched the iShares S&P 500 Top 20 UCITS ETF (SP20) in November of 2024, capturing the largest companies within the S&P 500 index.
The iShares NASDAQ 100 Top 30 UCITS ETF (QTOP), which tracks the 30 largest companies in the Nasdaq-100 index, launched shortly thereafter.
Elsewhere, Franklin Templeton launched an S&P 500 ETF and an S&P World ETF with ESG tilts. The Franklin S&P 500 Screened UCITS ETF (SP5S) and Franklin S&P World Screened UCITS ETF (SPWR) were listed in April 2025 with total expense ratios of 0.09% and 0.14%, respectively.
This article was originally published at etf.com sister publication ETF Stream.Permalink | © Copyright 2025 etf.com. All rights reserved
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Why Plug Power Stock Keeps Going Up
Plug Power is teaming up with Australian partner Allied Green Ammonia to build a hydrogen plant in Uzbekistan. Plug Power's CFO just bought 650,000 more shares of the company. The CFO now owns 2.6 million Plug shares, which are worth a lot more than they were worth on Friday. 10 stocks we like better than Plug Power › Are investors in Plug Power (NASDAQ: PLUG) stock irrationally exuberant? Yesterday, shares of the hydrogen fuel cell manufacturer surged to close 26% higher after announcing an expanded strategic collaboration with Australian partner Allied Green Ammonia, whereby the two companies will build a $5.5 billion green chemical production facility in Uzbekistan, and there produce electrolyzer to create hydrogen fuel. Today, Plug Power stock is up another 16% through 10:15 a.m. ET. Are any other catalysts fueling Plug Power's rise? Turns out, there are. Yesterday, I was unimpressed by Plug's announcement of the Uzbekistan project, which Plug boasted created a "5 GW partnership now spanning two continents" between itself and Allied Green Ammonia. After all, the companies' Australian project hasn't yet received a "final investment decision," while the Uzbekistan deal is in even earlier stages. It all seems very hypothetical to me. Plug Power's own CFO, Paul Middleton, though, seems to see things differently. In a sterling example of putting money where one's mouth is, Middleton yesterday purchased an additional 650,000 Plug Power shares on the open market, the same day the Uzbekistan deal was announced. Priced at $1.03 per share, that's a $672,000 bet that Plug Power stock is the real deal. And to drive the point home, Middleton added, "This additional investment reflects my strong conviction in Plug's strategy and long-term value creation." Still, there are other ways to view Middleton's investment. Middleton already owned nearly 2 million Plug shares before yesterday's purchase, which are now worth $0.43 per share more than they were worth last week. His net worth just jumped by more than $800,000. If nothing else, yesterday's news just created a lot of value for Plug's CFO. Before you buy stock in Plug Power, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Plug Power wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Plug Power Stock Keeps Going Up was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy
June 10, 2025Announcement no. 16 BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy COPENHAGEN, DENMARK and BOSTON, MA, USA, June 10, 2025, (GLOBE NEWSWIRE) - BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR) today announced the appointment of Carsten Buhl as Chief Executive Officer (CEO) of BioPorto A/S and its subsidiaries, effective 1 September 2025, as part of the Company's succession planning strategy. BioPorto's current CEO, Peter Mørch Eriksen, will remain in his position until 1 September 2025. Following this date, Peter Mørch Eriksen will support the incoming CEO during the transition period to ensure a smooth and effective onboarding process. Carsten Buhl has spent more than 25 years in the MedTech/life science industries, recently as President of Americas at WSAudiology and part of its executive management. Further, Carsten has experience from senior leadership positions at Natus Medical Inc, Ambu and GN Store Nord. Jens Due Olsen, Chair of BioPorto, stated: "I am pleased to welcome Carsten Buhl to BioPorto. Carsten will be instrumental in launching ProNephro AKI (NGAL)™ in the US market, driving revenue growth and finalizing the clinical studies & submitting an FDA application for adult use in 2026. With a strong background in MedTech/life science, Carsten has a proven track record of driving growth, innovation, and operational excellence. Carsten will be a solid addition to the BioPorto team.' Carsten Buhl, BioPorto's incoming CEO, commented: 'I am excited to join BioPorto at this amazing point in its journey, and look forward together with the BioPorto team to materialize the full potential of the Company's biomarker tests within kidney health, critical tests that can improve the clinical and economic outcomes for patients, providers, and healthcare ecosystem globally." Jens Due Olsen added: 'I want to extend my gratitude to and thank Peter for his dedication and important contributions to BioPorto. During this second tenure, significant milestones have been achieved — including the development of a comprehensive Corporate Strategy Plan, securing revenue growth, preparation for the commercial launch of ProNephro AKI (NGAL) in the US, advancement of the clinical trial for adult use, and securing successive critical financing rounds for the Company. These accomplishments have laid a robust foundation for BioPorto's continued growth and success.' To receive BioPorto's Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on Investor Relations Contacts Hanne S. Foss, Head of Investor Relations, BioPorto A/S, investor@ C: +45 26368918 About BioPorto BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company's flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit Forward looking statement disclaimer Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company's expectations, intentions and projections regarding its future performance including the Company's Guidance for 2025; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company's ability to successfully market both new and existing products. These forward-looking statements, which may use words such as 'aim', 'anticipate', 'believe', 'intend', 'estimate', 'expect' and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company's business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto's success are more fully disclosed in BioPorto's periodic financial filings, including its Annual Report for 2024, particularly under the heading 'Risk Factors'. Attachment 2025 06 10 - Announcement no. 16 - UKError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
an hour ago
- Miami Herald
NATO Ally Scraps Purchase of US Black Hawk Helicopters
Poland has scrapped plans to buy more S-70i Black Hawk helicopters as Warsaw rethinks its strategy for fighting a battle-hardened Russia pouring massive investment into its military. Poland has become a military powerhouse, leading the NATO alliance on defense spending. The country, which is situated on NATO's eastern flank, has felt the reverberations of more than three years of war in Ukraine, repeatedly scrambling fighter jets in response to intensive Russian airstrikes on parts of western Ukraine. Warsaw has been one of Kyiv's most strident supporters. NATO officials, particularly those from country's forming NATO's eastern edge, have increasingly warned Moscow could mount an attack against the alliance in the coming years, particularly if the U.S. succeeds in brokering a ceasefire in Ukraine. The Polish military changed its "priorities" for its upcoming purchases after "intensive" analysis, said General Wiesław Kukuła, the Chief of the General Staff for the Polish armed forces. "The aim of these changes is to better adapt to the challenges of the future battlefield," Kukuła told reporters on Friday. Warsaw will prioritize training and combat helicopters, as well as multi-use helicopters able to land on ships, heavy transport helicopters for the country's land forces and search and rescue aircraft, Kukuła added. Poland may look at buying other equipment, like drones or tanks, rather than the S-70i multirole helicopter, Grzegorz Polak, a spokesperson for the Polish Armament Agency, told Reuters. The war in Ukraine has spurred on drone advancement at astonishing speeds, while both sides have still relied heavily on the use of tanks and armored vehicles. Poland's previous government said in mid-2023 it was starting the process to buy more Black Hawk helicopters from PZL Mielec, a Polish branch of Lockheed Martin. Secretary of State for Poland's Ministry of National Defense Paweł Bejda said reports that a contract for the Black Hawk helicopters had been "canceled" were false, but the country's Armament Agency had decided to "terminate the procurement process." Kukuła pointed on Friday to the Polish purchase of 32 next-generation F-35 fighter jets and tens of advanced Apache helicopters that would soon "land on Polish soil" as part of preparations for the "future battlefield." Paweł Bejda, Secretary of State for Poland's Ministry of National Defense, said during a press conference on Friday: "The geopolitical situation, the situation in the east—the war in Ukraine, what Russia is currently buying, equipping its army—and everything that our air forces are carrying out during tasks connected to the NATO system, is being analyzed." Brigadier General Artur Kuptel, the head of Poland's Armaments Agency, told the media: "The priorities we have heard about today will give light for the coming days, for the coming months, in terms of the directions of activities in the area of helicopter aviation." Poland ordered nearly 100 AH-64E advanced Apache helicopters from Boeing in mid-2024, which the aerospace giant said would "strengthen Poland's operational capability and interoperability with the U.S., NATO and allied nations." Warsaw is expected to receive its first F-35 fifth-generation fighter jets from the U.S. next year. Related Articles Poland Election: Ukraine Skeptic Candidate Swings Surprise VictoryDonald Trump-Backed Candidate Wins Poland's Presidential ElectionMap Shows Countries in Europe Easiest for Americans to Get Dual CitizenshipNATO Scrambles Fighter Jets After Long-Range Russian Missile Strikes 2025 NEWSWEEK DIGITAL LLC.
